Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-674-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.88 million
Profitability
Miscellaneous
Employees255
Next Earnings Date3/21/2019 (Estimated)
OptionableOptionable
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) issued its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.16. View Agenus' Earnings History.
When is Agenus' next earnings date?
Has Agenus been receiving favorable news coverage?
Media coverage about AGEN stock has been trending positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the company's share price in the near term.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Alector (ALEC), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Audentes Therapeutics (BOLD), Rubius Therapeutics (RUBY), Coherus Biosciences (CHRS), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), Novavax (NVAX) and BAVARIAN NORDIC/S (BVNRY).
What other stocks do shareholders of Agenus own?
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
- Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
- Dr. Robert B. Stein, Sr. R&D Advisor (Age 68)
- Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
Who are Agenus' major shareholders?
Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include RTW Investments LP (8.45%), BlackRock Inc. (5.71%), D. E. Shaw & Co. Inc. (2.06%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.89%) and Millennium Management LLC (0.85%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus.
Which institutional investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Northern Trust Corp, Virtus ETF Advisers LLC, Barclays PLC, California Public Employees Retirement System, Virtu Financial LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Agenus.
Which institutional investors are buying Agenus stock?
AGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Millennium Management LLC, RTW Investments LP, Geode Capital Management LLC, Two Sigma Investments LP, Bank of New York Mellon Corp and Bank of America Corp DE. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $2.98.
How big of a company is Agenus?
Agenus has a market capitalization of $357.60 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.
What is Agenus' official website?
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
